Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Synthes-Stratec considers appealing German block:

This article was originally published in Clinica

Executive Summary

Synthes-Stratec, the Swiss orthopaedic trauma products group, has had its acquisition of fellow Swiss group Mathys Medical blocked by competition regulators in Germany, the only country where the firms' activities overlap. Synthes-Stratec chairman and CEO Hansjorg Wyss said the company was "prepared to appeal this prohibition decision". Synthes believes that the merger does not have a negative effect on the German trauma market segment. However, the Bundeskartellamt said it would create a dominant position. The company said it would "carefully analyse the reasons for the prohibition" before making further comment. It has already closed the deal in the rest of the world (see Clinica No 1095, p 15).





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts